New horizons in next-generation small molecule kinase inhibitors
In the pre-imatinib (Glivec®) era, two out of three patients…
In the pre-imatinib (Glivec®) era, two out of three patients died within five years from chronic myeloid leukemia and there was no hope for a curative treatment. Imatinib’s introduction in 2001 marked a breakthrough – as the first approved kinase inhibitor, it was a game-changer in cancer therapy and revolutionised…